

KING PHARMACEUTICALS INC

Form 8-K

April 08, 2003

**Table of Contents**

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 31, 2003

**King Pharmaceuticals, Inc.**

(Exact name of registrant as specified in its charter)

**Tennessee**  
(State or other jurisdiction  
of incorporation)

**0 24425**  
(Commission  
File Number)

**54-1684963**  
(IRS Employer  
Identification Number)

**501 Fifth Street, Bristol, Tennessee**  
(Address of principal executive offices)

**37620**  
(Zip Code)

Registrant's telephone number, including area code: **423-989-8000**

Not Applicable  
(Former name or former address, if changed since last report)

---

---

**TABLE OF CONTENTS**

SIGNATURE

Exhibit Index

EX-99.1 PRESS RELEASE

---

**Table of Contents**

**Item 5. Other Events**

On March 31, 2003, King Pharmaceuticals, Inc., a Tennessee corporation, announced that it filed a Form 12b-25 with the Securities and Exchange Commission (the SEC) providing for a 15-calendar-day extension for submitting its Form 10-K for the year ended December 31, 2002, to the SEC. On March 31, 2003, King issued a press release regarding the extension.

**Item 7. Financial Statements, Pro Forma Financial Information and Exhibits**

(a) Financial Statements on Businesses Acquired.

None.

(b) Pro Forma Financial Information.

None.

(c) Exhibits.

The following exhibits are filed pursuant to Item 601 of Regulation S-K:

**Exhibits:**

<b>Exhibit Number</b>	<b>Description of Exhibit</b>
99.1	Press Release of King Pharmaceuticals, Inc. dated March 31, 2003.

---

**Table of Contents**

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: April 7, 2003

KING PHARMACEUTICALS, INC.

By: /s/ James R. Lattanzi  
James R. Lattanzi  
Chief Financial Officer

---

**Table of Contents**

**Exhibit Index**

<b>Exhibit Number</b>	<b>Description of Exhibit</b>
99.1	Press Release of King Pharmaceuticals, Inc. dated March 31, 2003.